14:00 – 14:02 Welcome and Introduction TBC 14:02 – 14:12 The Cost of Delayed Diagnosis – Establishing the Economic Case for Early T1D Detection TBC
14:00 – 14:30 Scaling CGM Across Care: RCT Results of CGM in Non-Insulin Treated Type 2 Diabetes and Population-Health Pathways Thomas Martens (USA) Frederico Bertuzzi
Chairs: Jason Baker (USA), Nikolas Hillenbrand (DEU) 11:15 – 11:25 Teplizumab in treatment of T1D: Why Stage 2 autoimmune T1D management is changing Jason Baker
Chair: Ramzi Ajjan (GBR) 11:15 – 11:45 From Evidence to Standard of Care: CGM Beyond MDI in Every Type 2 Diabetes Care Plan Emma Wilmot
Chairs: Dario Pitocco (ITA), César Esteves (PRT) 7:45 – 7:50 Introduction Dario Pitocco (ITA)César Esteves (PRT) 7:50 – 8:05 Beyond alarms: Predicting and preventing nocturnal
Chair: Roman Hovorka (GBR) 07:15 – 07:35 Real-world pregnancy outcomes in type 1 diabetes Helen Murphy (GBR) 07:35 – 07:55 Menstrual cycle mapping with myLoop
Chair: Nemencio Nicodemus (PHL) 07:15 – 07:20 Introduction Nemencio Nicodemus (PHL) 07:20 – 07:45 Metformin effect on diabetes prevention Linong Ji (CHN) 07:45 – 08:10
Chair: Raffaella Buzzetti (ITA) 18:15 – 18:20 Introduction Raffaella Buzzetti (ITA) 18:20 – 18:50 From Need to Innovation: Why Ketones Matter in Diabetes Management Kirsten Nørgaard
Chair: Jaime Almandoz (USA) 18:00 – 18:10 Opening the conversation on modern obesity treatments Jaime Almandoz (USA) 18:10 – 18:35 Oral and injectable semaglutide: weight
Chairs: Apostolos Tsapas (GRC), Melanie Davies (GBR) 18:00 – 18:05 Introduction Melanie Davies (GBR) 18:05 – 18:13 The Legacy Effect in T2D: Impact of early